Mark is responsible for strategy and planning of digital health solutions for Janssen R&D. He needs to facilitate multiple clinical study teams across therapeutic areas deciding what endpoints make the most sense to collect digitally and conduct a risk-benefit assessment of technologies.
The 3 step process sets the foundations for clinical study teams to hone in on digital clinical measures to detect meaningful change and framework for tech evaluations. It’s updating daily with new literature and technologies
